ProQR Therapeutics (PRQR) Capital Expenditures (2013 - 2026)

ProQR Therapeutics (PRQR) has reported Capital Expenditures for 14 consecutive years, with $186624.5 the latest figure, recorded in Q1 2026.

• Quarterly Capital Expenditures fell 26.79% year-over-year to $186624.5 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (down 44.64% YoY) and the FY2025 annual result came in at $1.2 million, down 28.07% from the prior year.
• Capital Expenditures declined to $186624.5 in Q1 2026 per PRQR's latest filing, from $1.7 million in the prior quarter.
• Over the last five years, Capital Expenditures for PRQR reached as high as $3.1 million in Q4 2024 and fell as low as -$832982.5 in Q1 2024.
• A 5-year average of $425260.2 and a median of $114933.4 in 2025 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2022 — Capital Expenditures surged 862.5% — and 2024, when it sank 438.24%.
• Year by year, Capital Expenditures stood at $1.6 million in 2022, then surged by 49.76% to $2.4 million in 2023, then gained by 26.31% to $3.1 million in 2024, then sank by 43.99% to $1.7 million in 2025, then plunged by 89.17% to $186624.5 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $186624.5, $1.7 million, and -$192314.3 for Q1 2026, Q4 2025, and Q3 2025 respectively.